| Literature DB >> 35646417 |
Changwoo Yu1, So-Hye Hong1, Jin Hee Lee1, Ki Kyung Jung1, Jae-Ho Oh1, Jayoung Jeong1, HoonJeong Kwon2,3, Jong-Koo Kang4,5, Jun-Young Yang1.
Abstract
Sub-chronic toxicity studies using rats have been conducted for Cynanchum wilfordii (Maxim.) Hemsley (CW) and Cynanchum auriculatum Royle ex Wight (CA). CW water extract didn't show any adverse effects whereas administering CW powder decreased body weights in complication with decreased food consumptions. In the case of CA water extract, triglyceride and absolute/relative liver weights were elevated and vacuolation was observed in liver. Treated CA powder in male rats increased alanine aminotransferase and aspartate aminotransferase and induced single cell necrosis and multinucleated hepatocyte in liver. As for female rats, increased absolute/relative weights and hypertrophy/vacuolation in adrenal glands and vacuolation in ovaries were observed when administered CA powder. In conclusion, no observed adverse effect level (NOAEL) of CW water extract was over 5000 mg/kg/day, while NOAEL of CW powder was 700 mg/kg/day for female and 150 mg/kg/day for male. In case of CA, NOAEL of water extract was 1500 mg/kg/day for male and 2000 mg/kg/day for female, while NOAEL of powder was 150 mg/kg/day for both gender. To the best of our knowledge, this is the first sub-chronic toxicity study on the adverse effects, target organs and its dose levels of C. wilfordii (Maxim.) Hemsley and C. auriculatum Royle ex Wight following GLP protocols.Entities:
Keywords: Baeksuo; Cynanchum auriculatum Royle ex wight; Cynanchum wilfordii (Maxim.) Hemsley; Iyeopupiso; Sub-chronic toxicity
Year: 2022 PMID: 35646417 PMCID: PMC9133291 DOI: 10.1007/s10068-022-01072-5
Source DB: PubMed Journal: Food Sci Biotechnol ISSN: 1226-7708 Impact factor: 3.231
Fig. 1Sample preparation workflow of Cynanchum wilfordii (Maxim.) Hemsley and Cynanchum auriculatum Royle ex Wight
Fig. 2Body weights for female rats in 90-day gavage study of Cynanchum wilfordii (Maxim.) Hemsley powder. *,**Significantly different 500 mg/kg/day (left) and 700 mg/kg/day (right) treatment group from control group by Dunnett’s t-test (p < 0.05, p < 0.01)
Body weight changes for rats in 90-day gavage study of Cynanchum wilfordii (Maxim.) Hemsley powder
| Week | Control | 50 mg/kg/day | 150 mg/kg/day | 500 mg/kg/day | 700 mg/kg/day |
|---|---|---|---|---|---|
| n | 10 | 10 | 10 | 10 | |
| Female | |||||
| 0 | 21.3 ± 2.0 | 21.1 ± 1.8 | 21.3 ± 3.0 | 20.7 ± 2.2 | 21.3 ± 2.0 |
| 1 | 22.3 ± 1.0 | 21.7 ± 2.1 | 22.5 ± 1.6 | 18.8 ± 1.7** | 18.0 ± 1.8** |
| 2 | 24.6 ± 2.5 | 23.6 ± 2.0 | 23.9 ± 1.9 | 20.8 ± 1.9** | 20.3 ± 1.9** |
| 3 | 25.3 ± 2.4 | 24.3 ± 2.3 | 24.8 ± 2.0 | 21.5 ± 2.3** | 21.3 ± 2.3** |
| 4 | 26.0 ± 3.1 | 24.7 ± 2.4 | 25.4 ± 1.9 | 21.9 ± 2.1** | 22.2 ± 1.7** |
| 5 | 25.9 ± 2.8 | 24.8 ± 2.5 | 24.8 ± 2.1 | 21.5 ± 2.1** | 22.6 ± 2.5* |
| 6 | 25.7 ± 2.4 | 24.7 ± 2.8 | 24.6 ± 2.4 | 21.7 ± 2.3** | 23.0 ± 3.1 |
| 7 | 25.0 ± 2.2 | 23.8 ± 2.3 | 24.8 ± 2.8 | 21.0 ± 1.9** | 22.6 ± 2.1 |
| 8 | 24.9 ± 2.3 | 25.0 ± 3.0 | 24.6 ± 2.1 | 21.8 ± 1.7* | 23.7 ± 2.4 |
| 9 | 23.3 ± 2.0 | 23.4 ± 2.5 | 22.7 ± 2.2 | 20.4 ± 2.1* | 22.8 ± 2.6 |
| 10 | 23.1 ± 1.9 | 23.6 ± 2.9 | 23.2 ± 2.4 | 21.2 ± 1.9 | 23.0 ± 2.7 |
| 11 | 23.9 ± 2.2 | 22.8 ± 5.8 | 23.4 ± 2.0 | 22.1 ± 2.3 | 24.6 ± 1.7 |
| 12 | 22.9 ± 1.9 | 21.2 ± 7.3 | 21.6 ± 1.9 | 20.1 ± 1.4# | 20.9 ± 2.6 |
| 13 | 21.2 ± 1.7 | 22.7 ± 3.1 | 21.4 ± 1.5 | 20.2 ± 1.6 | 21.8 ± 2.8 |
*,**Significantly different from control group by Dunnett’s t-test (p < 0.05, p < 0.01)
#Significantly different from control group by Steel test (p < 0.05)
Significant changes and histopathology results for male rats in 90-day gavage study of Cynanchum auriculatum Royle ex Wight water extract
| Control | 500 mg/kg/day | 1000 mg/kg/day | 2000 mg/kg/day | |
|---|---|---|---|---|
| Clinical chemistry | ||||
| Triglyceride (mg/dL) | 54 ± 27 | 79 ± 34 | 68 ± 17 | 86 ± 16* |
| Organ weights | ||||
| Liver | ||||
| Absolute (g) | 14.52 ± 1.46 | 16.57 ± 1.39** | 15.64 ± 1.29 | 16.63 ± 1.59** |
| Relative (g/100 g bw) | 2.52 ± 0.14 | 2.64 ± 0.12 | 2.60 ± 0.16 | 2.74 ± 0.14** |
| Histopathology | ||||
| Liver | ||||
| Periportal microvesicular vacuolation, hepatocyte | 10 | 7 | 8 | 10 |
| Minimal | 7 | 6 | 3 | 1 |
| Slight | 1 | – | 5 | 7 |
| Moderate | 2 | 1 | – | 2 |
*,**Significantly different from control group by Dunnett’s t-test (p < 0.05, p < 0.01)
Fig. 3Histopathological examinations treating Cynanchum auriculatum Royle ex Wight water extract (A: Liver from male control group, B: Liver from 2000 mg/kg/day treatment group (periportal microvesicular vacuolation hepatocyte))
Significant changes for rats in 90-day gavage study of Cynanchum auriculatum Royle ex Wight powder
| Control | 50 mg/kg/day | 150 mg/kg/day | 500 mg/kg/day | |
|---|---|---|---|---|
| n | 10 | 10 | 10 | 10 |
| Male | ||||
| Clinical chemistry | ||||
| Alanine aminotransferase (U/L) | 30.3 ± 5.9 | 29.6 ± 4.3 | 33.5 ± 11.0 | 207.5 ± 144.8** |
| Aspartate aminotransferase (U/L) | 95.2 ± 22.2 | 96.3 ± 21.5 | 93.4 ± 16.8 | 484.2 ± 417.2** |
| Female | ||||
| Organ weights | ||||
| Adrenal glands | ||||
| Absolute (g) | 0.0702 ± 0.0077 | 0.0751 ± 0.0082 | 0.0719 ± 0.0091 | 0.0883 ± 0.0105** |
| Relative (g/100 g bw) | 0.0223 ± 0.0025 | 0.0249 ± 0.0025 | 0.0237 ± 0.0020 | 0.0301 ± 0.0035** |
**Significantly different from control group by Dunnett’s t-test (p < 0.01)
Histopathological findings for rats in 90-day gavage study of Cynanchum auriculatum Royle ex Wight powder
| Control | 50 mg/kg/day | 150 mg/kg/day | 500 mg/kg/day | |
|---|---|---|---|---|
| n | 10 | 10 | 10 | 10 |
| Male | ||||
| Liver | ||||
| Multinucleated hepatocyte | 0 | 0 | 0 | 2 |
| Single cell necrosis | 0 | 0 | 0 | 5*** |
| Female | ||||
| Adrenal glands | ||||
| Hypertrophy/vacuolation, zona fasciculata | 0 | 0 | 0 | 3*** |
| Ovaries | ||||
| Vacuolation, interstitial and theca cells | 0 | 0 | 0 | 5*** |
***Significantly different from control group by Kruskal–Wallis and Mann–Whitney U-test (p < 0.05)
Fig. 4Histopathological examinations treating Cynanchum auriculatum Royle ex Wight powder (A: Liver from male control Group, B: Liver from 500 mg/kg/day treatment group (Multinucleated hepatocytes), C: Adrenal gland from female control group, D: Adrenal gland from 500 mg/kg/day treatment group (Hypertrophy/vacuolation, zona fasciculata), E: Ovary from female control group, F: Ovary from 500 mg/kg/day treatment group (Vacuolation, interstitial and theca cell))